clinical trial · NCT06372717
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Acute Myeloid Leukemia RefractoryMyelodysplastic Syndrome Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess BlastsAcute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia (AML)APL-4098Azacitidine and APL-4098Azacitidine and Venetoclax and APL-4098
brief summary
This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB).
started
Jun 4, 2024
primary completion
Mar 1, 2027
completion
May 1, 2027
last updated
Feb 4, 2026
official title
A Phase 1 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and in Combination With Azacitidine and in Combination With Azacitidine Plus Venetoclax in Adults With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol